Global Biologics Market size valued at USD 428.71 Bn. in 2024, projected to reach USD 860.52 Bn. by 2032, growing at 9.1% CAGR.Biologics Market Overview
Biologics are pharmaceutical products derived from living organisms, including proteins, cells, or tissues, used to prevent, treat, or cure diseases. They include vaccines, monoclonal antibodies, and gene therapies. The global biologics market is experiencing robust growth due to their increasing prevalence of chronic diseases, advancements in biotechnology, and rising demand for personalized medicine. A key market driver is the growing adoption of biosimilars, which gives a cost-effective alternative to expensive biologic therapies. North America dominates the Biologics Market by its strong R&D investments, favorable regulatory policies, and presence of leading pharmaceutical companies like Johnson & Johnson, Roche, and AbbVie. Also, the Asia Pacific region is emerging as a high-growth market thanks to its expanding healthcare infrastructure and increasing biopharmaceutical production. Key players are focusing on innovation and strategic collaborations to strengthen their market position. The report also helps in understanding the Global Biologics Market dynamics, structure by analyzing the market segments and projects the Global market. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Biologics Market makes the report an investor’s guide.To know about the Research Methodology :- Request Free Sample Report
Biologics Market Dynamics
Billion-Dollar Investments, Breakthrough Treatments, and Strong Revenue Growth to drive the Biologics Market growth
In the past five years, over US$1.5 billion has been invested by the top 10 pharmaceutical giants, which have been interpreted into capacity expansion and focused research and development. Pharmaceutical companies are earning strong revenues through the best prices, increasing their profit margins by xx%. Factors like product approvals and the ability of biologics to effectively treat significantly complex diseases, which was close to incredible earlier, have been key for market growth. Pharmaceutical companies patenting biologics products have been projected to make healthy gains during the forecast period.Rising Approval Rates and Blockbuster Biologics to drive the Biologics Market growth
With the vigorous growth in the biopharmaceutical industry, over 14% of biomolecules that enter phase I of clinical trials are expected to be approved as a drug. Growing annual product approvals and a strong biologics channel have been an indication of robust development of the world market. For example, the anti-inflammatory drug Humira is not only the best-selling drug, but it is also one of the best-selling drugs globally. But, high capital investment is essential for research and development could hinder the demand in the international market.High Costs and Complex Regulations Limit Market Entry to Restrain the Biologics Market
Only biopharmaceutical companies have been observed to enter the market because of a costly initial setup. A successful product launch primarily requires an over US$1.0 billion investment and takes nearly 9 years. Furthermore, the regulatory approval of biologics is quite detailed since the molecules are complex.Competitive Pricing, Innovation, and Strategic Alliances to create Biologics Market Opportunity
Manufacturers in Biologics are focusing on competitive pricing as a strategy to capture significant market share. Moreover, strategic mergers and acquisitions, and technological innovations are also the key focus areas of the manufacturers.Biologics Market Segment Analysis
Based on Product, the global market is segmented into Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cell Therapy, and Gene Therapy. The Monoclonal Antibodies segment held the largest market share of 42.9% in 2024. Extensive growth is credited to the increasing demand for personalized therapies in various regions. Additionally, extensive research in antibodies to discover targeted therapies for a variety of diseases, like different types of infections, cancers, and various immunological disorders, is projected to propel the market. Based on disease category, the global Biologics market is segmented into Oncology, Infectious Diseases, Immunology, and Autoimmune Diseases. The Immunology segment held the largest market share of xx% in 2024, and it is expected to grow at the highest CAGR of xx% in the global Biologics market during the forecast period. Biologics are utilised to treat autoimmune illnesses such as inflammatory arthritis, rheumatoid arthritis, and psoriatic arthritis, which is driving the market growth.Biologics Market Regional Analysis
North America held the largest market share of 51% in 2024 and is expected to remain its leading position in the global Biologics market during the forecast period. Because growth in this regional market is attributed to intensive research and development activities, novel drug formulations, and a large number of clinical trials focused on large-molecule drug discovery. Asia Pacific held the 2nd largest market share of 21% in 2024. Because of the rising prevalence of chronic conditions such as diabetes, as well as increased number of healthcare tourists in the regions of the world. The objective of the report is to present a comprehensive analysis of the global Biologics Market to the stakeholders in the industry. The past and current status of the industry, with the forecasted market size and trends, are presented in the report, with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the global Market dynamics, structure by analyzing the market segments and projecting the global Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global Market makes the report an investor’s guide.Biologics Market Competitive Landscape
The top key players in the biologics market include AbbVie, Amgen, Pfizer, and Johnson & Johnson, each leading due to strong R&D capabilities and strategic focus. AbbVie maintains dominance with a shift from Humira to newer biologics like Skyrizi and Rinvoq, backed by an R&D investment of around $6–7 billion annually. Amgen focuses on biosimilars and advanced biologic engineering in oncology and inflammation, investing about $5 billion in R&D. Pfizer leads with mRNA advancements post-COVID-19 and expanded its biologics pipeline through the acquisition of Seagen, spending nearly $10–12 billion on R&D annually. Johnson & Johnson excels with innovative biologics in the autoimmune and oncology areas, with an R&D spend exceeding $14 billion. These companies are considered top players due to their diversified portfolios, consistent biologic drug approvals, and high investment in next-gen biologic technologies, ensuring strong market presence and long-term growth.Biologics Market Key Trends
Key Trends Description Rise of Biosimilars Increased adoption of cost-effective biosimilars is intensifying competition and expanding access to biologic treatments globally. Advancements in Monoclonal Antibodies Monoclonal antibody innovations are enhancing precision in treatment, especially in oncology, autoimmune diseases, and chronic illnesses. Personalized Medicine Growth Biologics tailored to genetic profiles are driving demand for personalized therapies, improving treatment outcomes and patient compliance. Biologics Market Recent Developments
• On January 23, 2025, AbbVie completed its acquisition of Nimble Therapeutics, bringing in a preclinical oral peptide IL‑23R inhibitor and Nimble’s peptide R&D platform. • On May 31, 2025, Moderna had the FDA approve mRNA‑1283 (branded mNEXSPIKE), a new lower-dose COVID-19 vaccine, for use in adults 65+ and high-risk individuals aged 12–64, based on Phase 3 efficacy showing ~9.3% greater efficacy than its predecessor. • On January 9, 2025, Samsung Biologics extended its collaboration with LigaChem Biosciences, committing its new dedicated ADC facility (500 L reactor) to support LigaChem’s ADC pipeline development.Global Biologics Market Scope: Inquire before buying
Biologics Market Report Coverage Details Base Year: 2024 Forecast Period: 2025-2032 Historical Data: 2019 to 2024 Market Size in 2024: USD 428.71 Bn. Forecast Period 2025 to 2032 CAGR: 9.1% Market Size in 2032: USD 860.52 Bn. Segments Covered: by Disease Category Oncology, Infectious Diseases, Immunological Disorders Cardiovascular Disorders Hematological Disorders Others by Manufacturing In-house Outsource by Product Monoclonal Antibodies Vaccines Recombinant Proteins Antisense, RNAi, & Molecular Therapy Others by Source Microbial Mammalian Others Biologics Market, By Region
North America (United States, Canada and Mexico) Europe (United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, Rest of Europe) Asia Pacific (China, Japan, South Korea, India, Australia, Malaysia, Thailand, Vietnam, Indonesia, Philippines, Rest of APAC) Middle East and Africa (South Africa, GCC, Nigeria, Egypt, Turkey, Rest of MEA) South America (Brazil, Argentina, Colombia, Chile, Peru, Rest of South America)Biologics Market key players are:
North America 1. AbbVie (USA) 2. Amgen (USA) 3. Biogen (USA) 4. Coherus BioSciences (USA) 5. Eli Lilly (USA) 6. Merck & Co. (USA) 7. Pfizer (USA) 8. Johnson & Johnson (USA) 9. Moderna (USA) 10. Bristol-Myers Squibb (USA) Europe 11. F. Hoffmann-La Roche (Switzerland) 12. Novartis (Switzerland) 13. GlaxoSmithKline (UK) 14. AstraZeneca (UK) 15. Bayer (Germany) 16. Boehringer Ingelheim (Germany) 17. Fresenius Kabi (Germany) Asia Pacific 18. Biocon (India) 19. Dr. Reddy’s Laboratories (India) 20. Intas Pharmaceuticals (India) 21. Lupin (India) 22. Celltrion (South Korea) 23. Samsung Biologics (South Korea) 24. LG Chem (South Korea) 25. Genor Biopharma (China) Middle East & Africa 26. Julphar (UAE) South America 27. mAbxience (Argentina) 28. Eurofarma (Brazil) 29. Libbs Farmacêutica (Brazil) 30. Blau Farmacêutica (Brazil)Frequently Asked Questions
1] What segments are covered in the Biologics Market report? Ans. The segments covered in the Biologics Market report are based on Product, Disease Category, Manufacturing, and Source. 2] Which region is expected to hold the highest share in the global Biologics Market? Ans. North America is expected to hold the highest share in the global Biologics Market. 3] Who are the top key players in the global Biologics Market? Ans. Sandoz, Pfizer, Teva Pharmaceutical, Celltrion, and Biocon are the top key players in the global Biologics Market. 4] What was the market size of the global Biologics Market in 2024? Ans. The market size of the global Biologics Market in 2024 was USD 428.71 Bn. 5] By Application, what segments are covered in the global Biologics Market report? Ans. The segments covered in the global Biologics Market report by application are Oncology, Infectious Diseases, Immunology, and Autoimmune Diseases.
1. Biologics Market Introduction 1.1. Study Assumptions and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Biologics Market: Competitive Landscape 2.1. Ecosystem Analysis 2.2. MMR Competition Matrix 2.3. Competitive Landscape 2.4. Key Players Benchmarking 2.4.1. Company Name 2.4.2. Business Segment 2.4.3. End-user Segment 2.4.4. Revenue (2024) 2.4.5. Company Locations 2.5. Market Structure 2.5.1. Market Leaders 2.5.2. Market Followers 2.5.3. Emerging Players 2.6. Mergers and Acquisitions Details 2.7. KANO Model Analysis 3. Global Biologics Market: Dynamics 3.1. Region-wise Trends of the Biologics Market 3.1.1. North America Biologics Market Trends 3.1.2. Europe Biologics Market Trends 3.1.3. Asia Pacific Biologics Market Trends 3.1.4. Middle East and Africa Biologics Market Trends 3.1.5. South America Biologics Market Trends 3.2. Biologics Market Dynamics 3.2.1. Global Biologics Market Drivers 3.2.1.1. Rising chronic diseases 3.2.1.2. Personalized medicine demand 3.2.2. Global Biologics Market Restraints 3.2.3. Global Biologics Market Opportunities 3.2.3.1. Biosimilar expansion 3.2.3.2. Emerging markets growth 3.2.4. Global Biologics Market Challenges 3.3. PORTER’s Five Forces Analysis 3.4. PESTLE Using Tree-Map Analysis 3.4.1. Biotech advancements 3.4.2. Sustainable production 3.5. Regulatory Landscape by Region 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. Middle East and Africa 3.5.5. South America 3.6. Key Opinion Leader Analysis for the Global Industry 3.7. Analysis of Government Schemes and Initiatives for Industry 4. Biologics Market: Global Market Size and Forecast by Segmentation (by Value in USD Billion) (2024-2032) 4.1. Biologics Market Size and Forecast, By Disease Category (2024-2032) 4.1.1. Oncology 4.1.2. Infectious Diseases 4.1.3. Immunological Disorders 4.1.4. Cardiovascular Disorders 4.1.5. Hematological Disorders 4.1.6. Others 4.2. Biologics Market Size and Forecast, By Manufacturing (2024-2032) 4.2.1. In-house 4.2.2. Outsource 4.3. Biologics Market Size and Forecast, By Product (2024-2032) 4.3.1. Monoclonal Antibodies 4.3.2. Vaccines 4.3.3. Recombinant Proteins 4.3.4. Antisense, RNAi, & Molecular Therapy 4.3.5. Others 4.4. Biologics Market Size and Forecast, By Source (2024-2032) 4.4.1. Microbial 4.4.2. Mammalian 4.4.3. Others 4.5. Biologics Market Size and Forecast, By Region (2024-2032) 4.5.1. North America 4.5.2. Europe 4.5.3. Asia Pacific 4.5.4. Middle East and Africa 4.5.5. South America 5. North America Biologics Market Size and Forecast by Segmentation (by Value in USD Billion) (2024-2032) 5.1. North America Biologics Market Size and Forecast, By Disease Category (2024-2032) 5.1.1. Oncology 5.1.2. Infectious Diseases 5.1.3. Immunological Disorders 5.1.4. Cardiovascular Disorders 5.1.5. Hematological Disorders 5.1.6. Others 5.2. North America Biologics Market Size and Forecast, By Manufacturing (2024-2032) 5.2.1. In-house 5.2.2. Outsource 5.3. North America Biologics Market Size and Forecast, By Product (2024-2032) 5.3.1. Monoclonal Antibodies 5.3.2. Vaccines 5.3.3. Recombinant Proteins 5.3.4. Antisense, RNAi, & Molecular Therapy 5.3.5. Others 5.4. North America Biologics Market Size and Forecast, By Source (2024-2032) 5.4.1. Microbial 5.4.2. Mammalian 5.4.3. Others 5.5. North America Biologics Market Size and Forecast, by Country (2024-2032) 5.5.1. United States 5.5.1.1. United States Biologics Market Size and Forecast, By Disease Category (2024-2032) 5.5.1.1.1. Oncology 5.5.1.1.2. Infectious Diseases 5.5.1.1.3. Immunological Disorders 5.5.1.1.4. Cardiovascular Disorders 5.5.1.1.5. Hematological Disorders 5.5.1.1.6. Others 5.5.1.2. United States Biologics Market Size and Forecast, By Manufacturing (2024-2032) 5.5.1.2.1. In-house 5.5.1.2.2. Outsource 5.5.1.3. United States Biologics Market Size and Forecast, By Product (2024-2032) 5.5.1.3.1. Monoclonal Antibodies 5.5.1.3.2. Vaccines 5.5.1.3.3. Recombinant Proteins 5.5.1.3.4. Antisense, RNAi, & Molecular Therapy 5.5.1.3.5. Others 5.5.1.4. United States Biologics Market Size and Forecast, By Source (2024-2032) 5.5.1.4.1. Microbial 5.5.1.4.2. Mammalian 5.5.1.4.3. Others 5.5.2. Canada 5.5.2.1. Canada Biologics Market Size and Forecast, By Disease Category (2024-2032) 5.5.2.1.1. Oncology 5.5.2.1.2. Infectious Diseases 5.5.2.1.3. Immunological Disorders 5.5.2.1.4. Cardiovascular Disorders 5.5.2.1.5. Hematological Disorders 5.5.2.1.6. Others 5.5.2.2. Canada Biologics Market Size and Forecast, By Manufacturing (2024-2032) 5.5.2.2.1. In-house 5.5.2.2.2. Outsource 5.5.2.3. Canada Biologics Market Size and Forecast, By Product (2024-2032) 5.5.2.3.1. Monoclonal Antibodies 5.5.2.3.2. Vaccines 5.5.2.3.3. Recombinant Proteins 5.5.2.3.4. Antisense, RNAi, & Molecular Therapy 5.5.2.3.5. Others 5.5.2.4. Canada Biologics Market Size and Forecast, By Source (2024-2032) 5.5.2.4.1. Microbial 5.5.2.4.2. Mammalian 5.5.2.4.3. Others 5.5.3. Mexico 5.5.3.1. Mexico Biologics Market Size and Forecast, By Disease Category (2024-2032) 5.5.3.1.1. Oncology 5.5.3.1.2. Infectious Diseases 5.5.3.1.3. Immunological Disorders 5.5.3.1.4. Cardiovascular Disorders 5.5.3.1.5. Hematological Disorders 5.5.3.1.6. Others 5.5.3.2. Mexico Biologics Market Size and Forecast, By Manufacturing (2024-2032) 5.5.3.2.1. In-house 5.5.3.2.2. Outsource 5.5.3.3. Mexico Biologics Market Size and Forecast, By Product (2024-2032) 5.5.3.3.1. Monoclonal Antibodies 5.5.3.3.2. Vaccines 5.5.3.3.3. Recombinant Proteins 5.5.3.3.4. Antisense, RNAi, & Molecular Therapy 5.5.3.3.5. Others 5.5.3.4. Mexico Biologics Market Size and Forecast, By Source (2024-2032) 5.5.3.4.1. Microbial 5.5.3.4.2. Mammalian 5.5.3.4.3. Others 6. Europe Biologics Market Size and Forecast by Segmentation (by Value in USD Billion) (2024-2032) 6.1. Europe Biologics Market Size and Forecast, By Disease Category (2024-2032) 6.2. Europe Biologics Market Size and Forecast, By Manufacturing (2024-2032) 6.3. Europe Biologics Market Size and Forecast, By Product (2024-2032) 6.4. Europe Biologics Market Size and Forecast, By Source (2024-2032) 6.5. Europe Biologics Market Size and Forecast, by Country (2024-2032) 6.5.1. United Kingdom 6.5.1.1. United Kingdom Biologics Market Size and Forecast, By Disease Category (2024-2032) 6.5.1.2. United Kingdom Biologics Market Size and Forecast, By Manufacturing (2024-2032) 6.5.1.3. United Kingdom Biologics Market Size and Forecast, By Product (2024-2032) 6.5.1.4. United Kingdom Biologics Market Size and Forecast, By Source (2024-2032) 6.5.2. France 6.5.2.1. France Biologics Market Size and Forecast, By Disease Category (2024-2032) 6.5.2.2. France Biologics Market Size and Forecast, By Manufacturing (2024-2032) 6.5.2.3. France Biologics Market Size and Forecast, By Product (2024-2032) 6.5.2.4. France Biologics Market Size and Forecast, By Source (2024-2032) 6.5.3. Germany 6.5.3.1. Germany Biologics Market Size and Forecast, By Disease Category (2024-2032) 6.5.3.2. Germany Biologics Market Size and Forecast, By Manufacturing (2024-2032) 6.5.3.3. Germany Biologics Market Size and Forecast, By Product (2024-2032) 6.5.3.4. Germany Biologics Market Size and Forecast, By Source (2024-2032) 6.5.4. Italy 6.5.4.1. Italy Biologics Market Size and Forecast, By Disease Category (2024-2032) 6.5.4.2. Italy Biologics Market Size and Forecast, By Manufacturing (2024-2032) 6.5.4.3. Italy Biologics Market Size and Forecast, By Product (2024-2032) 6.5.4.4. Italy Biologics Market Size and Forecast, By Source (2024-2032) 6.5.5. Spain 6.5.5.1. Spain Biologics Market Size and Forecast, By Disease Category (2024-2032) 6.5.5.2. Spain Biologics Market Size and Forecast, By Manufacturing (2024-2032) 6.5.5.3. Spain Biologics Market Size and Forecast, By Product (2024-2032) 6.5.5.4. Spain Biologics Market Size and Forecast, By Source (2024-2032) 6.5.6. Sweden 6.5.6.1. Sweden Biologics Market Size and Forecast, By Disease Category (2024-2032) 6.5.6.2. Sweden Biologics Market Size and Forecast, By Manufacturing (2024-2032) 6.5.6.3. Sweden Biologics Market Size and Forecast, By Product (2024-2032) 6.5.6.4. Sweden Biologics Market Size and Forecast, By Source (2024-2032) 6.5.7. Russia 6.5.7.1. Russia Biologics Market Size and Forecast, By Disease Category (2024-2032) 6.5.7.2. Russia Biologics Market Size and Forecast, By Manufacturing (2024-2032) 6.5.7.3. Russia Biologics Market Size and Forecast, By Product (2024-2032) 6.5.7.4. Russia Biologics Market Size and Forecast, By Source (2024-2032) 6.5.8. Rest of Europe 6.5.8.1. Rest of Europe Biologics Market Size and Forecast, By Disease Category (2024-2032) 6.5.8.2. Rest of Europe Biologics Market Size and Forecast, By Manufacturing (2024-2032) 6.5.8.3. Rest of Europe Biologics Market Size and Forecast, By Product (2024-2032) 6.5.8.4. Rest of Europe Biologics Market Size and Forecast, By Source (2024-2032) 7. Asia Pacific Biologics Market Size and Forecast by Segmentation (by Value in USD Billion) (2024-2032) 7.1. Asia Pacific Biologics Market Size and Forecast, By Disease Category (2024-2032) 7.2. Asia Pacific Biologics Market Size and Forecast, By Manufacturing (2024-2032) 7.3. Asia Pacific Biologics Market Size and Forecast, By Product (2024-2032) 7.4. Asia Pacific Biologics Market Size and Forecast, By Source (2024-2032) 7.5. Asia Pacific Biologics Market Size and Forecast, by Country (2024-2032) 7.5.1. China 7.5.1.1. China Biologics Market Size and Forecast, By Disease Category (2024-2032) 7.5.1.2. China Biologics Market Size and Forecast, By Manufacturing (2024-2032) 7.5.1.3. China Biologics Market Size and Forecast, By Product (2024-2032) 7.5.1.4. China Biologics Market Size and Forecast, By Source (2024-2032) 7.5.2. S Korea 7.5.2.1. S Korea Biologics Market Size and Forecast, By Disease Category (2024-2032) 7.5.2.2. S Korea Biologics Market Size and Forecast, By Manufacturing (2024-2032) 7.5.2.3. S Korea Biologics Market Size and Forecast, By Product (2024-2032) 7.5.2.4. S Korea Biologics Market Size and Forecast, By Source (2024-2032) 7.5.3. Japan 7.5.3.1. Japan Biologics Market Size and Forecast, By Disease Category (2024-2032) 7.5.3.2. Japan Biologics Market Size and Forecast, By Manufacturing (2024-2032) 7.5.3.3. Japan Biologics Market Size and Forecast, By Product (2024-2032) 7.5.3.4. Japan Biologics Market Size and Forecast, By Source (2024-2032) 7.5.4. India 7.5.4.1. India Biologics Market Size and Forecast, By Disease Category (2024-2032) 7.5.4.2. India Biologics Market Size and Forecast, By Manufacturing (2024-2032) 7.5.4.3. India Biologics Market Size and Forecast, By Product (2024-2032) 7.5.4.4. India Biologics Market Size and Forecast, By Source (2024-2032) 7.5.5. Australia 7.5.5.1. Australia Biologics Market Size and Forecast, By Disease Category (2024-2032) 7.5.5.2. Australia Biologics Market Size and Forecast, By Manufacturing (2024-2032) 7.5.5.3. Australia Biologics Market Size and Forecast, By Product (2024-2032) 7.5.5.4. Australia Biologics Market Size and Forecast, By Source (2024-2032) 7.5.6. Indonesia 7.5.6.1. Indonesia Biologics Market Size and Forecast, By Disease Category (2024-2032) 7.5.6.2. Indonesia Biologics Market Size and Forecast, By Manufacturing (2024-2032) 7.5.6.3. Indonesia Biologics Market Size and Forecast, By Product (2024-2032) 7.5.6.4. Indonesia Biologics Market Size and Forecast, By Source (2024-2032) 7.5.7. Malaysia 7.5.7.1. Malaysia Biologics Market Size and Forecast, By Disease Category (2024-2032) 7.5.7.2. Malaysia Biologics Market Size and Forecast, By Manufacturing (2024-2032) 7.5.7.3. Malaysia Biologics Market Size and Forecast, By Product (2024-2032) 7.5.7.4. Malaysia Biologics Market Size and Forecast, By Source (2024-2032) 7.5.8. Philippines 7.5.8.1. Philippines Biologics Market Size and Forecast, By Disease Category (2024-2032) 7.5.8.2. Philippines Biologics Market Size and Forecast, By Manufacturing (2024-2032) 7.5.8.3. Philippines Biologics Market Size and Forecast, By Product (2024-2032) 7.5.8.4. Philippines Biologics Market Size and Forecast, By Source (2024-2032) 7.5.9. Thailand 7.5.9.1. Thailand Biologics Market Size and Forecast, By Disease Category (2024-2032) 7.5.9.2. Thailand Biologics Market Size and Forecast, By Manufacturing (2024-2032) 7.5.9.3. Thailand Biologics Market Size and Forecast, By Product (2024-2032) 7.5.9.4. Thailand Biologics Market Size and Forecast, By Source (2024-2032) 7.5.10. Vietnam 7.5.10.1. Vietnam Biologics Market Size and Forecast, By Disease Category (2024-2032) 7.5.10.2. Vietnam Biologics Market Size and Forecast, By Manufacturing (2024-2032) 7.5.10.3. Vietnam Biologics Market Size and Forecast, By Product (2024-2032) 7.5.10.4. Vietnam Biologics Market Size and Forecast, By Source (2024-2032) 7.5.11. Rest of Asia Pacific 7.5.11.1. Rest of Asia Pacific Biologics Market Size and Forecast, By Disease Category (2024-2032) 7.5.11.2. Rest of Asia Pacific Biologics Market Size and Forecast, By Manufacturing (2024-2032) 7.5.11.3. Rest of Asia Pacific Biologics Market Size and Forecast, By Product (2024-2032) 7.5.11.4. Rest of Asia Pacific Biologics Market Size and Forecast, By Source (2024-2032) 8. Middle East and Africa Biologics Market Size and Forecast (by Value in USD Billion) (2024-2032 8.1. Middle East and Africa Biologics Market Size and Forecast, By Disease Category (2024-2032) 8.2. Middle East and Africa Biologics Market Size and Forecast, By Manufacturing (2024-2032) 8.3. Middle East and Africa Biologics Market Size and Forecast, By Product (2024-2032) 8.4. Middle East and Africa Biologics Market Size and Forecast, By Source (2024-2032) 8.5. Middle East and Africa Biologics Market Size and Forecast, by Country (2024-2032) 8.5.1. South Africa 8.5.1.1. South Africa Biologics Market Size and Forecast, By Disease Category (2024-2032) 8.5.1.2. South Africa Biologics Market Size and Forecast, By Manufacturing (2024-2032) 8.5.1.3. South Africa Biologics Market Size and Forecast, By Product (2024-2032) 8.5.1.4. South Africa Biologics Market Size and Forecast, By Source (2024-2032) 8.5.2. GCC 8.5.2.1. GCC Biologics Market Size and Forecast, By Disease Category (2024-2032) 8.5.2.2. GCC Biologics Market Size and Forecast, By Manufacturing (2024-2032) 8.5.2.3. GCC Biologics Market Size and Forecast, By Product (2024-2032) 8.5.2.4. GCC Biologics Market Size and Forecast, By Source (2024-2032) 8.5.3. Egypt 8.5.3.1. Egypt Biologics Market Size and Forecast, By Disease Category (2024-2032) 8.5.3.2. Egypt Biologics Market Size and Forecast, By Manufacturing (2024-2032) 8.5.3.3. Egypt Biologics Market Size and Forecast, By Product (2024-2032) 8.5.3.4. Egypt Biologics Market Size and Forecast, By Source (2024-2032) 8.5.4. Nigeria 8.5.4.1. Nigeria Biologics Market Size and Forecast, By Disease Category (2024-2032) 8.5.4.2. Nigeria Biologics Market Size and Forecast, By Manufacturing (2024-2032) 8.5.4.3. Nigeria Biologics Market Size and Forecast, By Product (2024-2032) 8.5.4.4. Nigeria Biologics Market Size and Forecast, By Source (2024-2032) 8.5.5. Rest of ME&A 8.5.5.1. Rest of ME&A Biologics Market Size and Forecast, By Disease Category (2024-2032) 8.5.5.2. Rest of ME&A Biologics Market Size and Forecast, By Manufacturing (2024-2032) 8.5.5.3. Rest of ME&A Biologics Market Size and Forecast, By Product (2024-2032) 8.5.5.4. Rest of ME&A Biologics Market Size and Forecast, By Source (2024-2032) 9. South America Biologics Market Size and Forecast by Segmentation (by Value in USD Billion) (2024-2032 9.1. South America Biologics Market Size and Forecast, By Disease Category (2024-2032) 9.2. South America Biologics Market Size and Forecast, By Manufacturing (2024-2032) 9.3. South America Biologics Market Size and Forecast, By Product (2024-2032) 9.4. South America Biologics Market Size and Forecast, By Source (2024-2032) 9.5. South America Biologics Market Size and Forecast, by Country (2024-2032) 9.5.1. Brazil 9.5.1.1. Brazil Biologics Market Size and Forecast, By Disease Category (2024-2032) 9.5.1.2. Brazil Biologics Market Size and Forecast, By Manufacturing (2024-2032) 9.5.1.3. Brazil Biologics Market Size and Forecast, By Product (2024-2032) 9.5.1.4. Brazil Biologics Market Size and Forecast, By Source (2024-2032) 9.5.2. Argentina 9.5.2.1. Argentina Biologics Market Size and Forecast, By Disease Category (2024-2032) 9.5.2.2. Argentina Biologics Market Size and Forecast, By Manufacturing (2024-2032) 9.5.2.3. Argentina Biologics Market Size and Forecast, By Product (2024-2032) 9.5.2.4. Argentina Biologics Market Size and Forecast, By Source (2024-2032) 9.5.3. Colombia 9.5.3.1. Colombia Biologics Market Size and Forecast, By Disease Category (2024-2032) 9.5.3.2. Colombia Biologics Market Size and Forecast, By Manufacturing (2024-2032) 9.5.3.3. Colombia Biologics Market Size and Forecast, By Product (2024-2032) 9.5.3.4. Colombia Biologics Market Size and Forecast, By Source (2024-2032) 9.5.4. Chile 9.5.4.1. Chile Biologics Market Size and Forecast, By Disease Category (2024-2032) 9.5.4.2. Chile Biologics Market Size and Forecast, By Manufacturing (2024-2032) 9.5.4.3. Chile Biologics Market Size and Forecast, By Product (2024-2032) 9.5.4.4. Chile Biologics Market Size and Forecast, By Source (2024-2032) 9.5.5. Rest Of South America 9.5.5.1. Rest Of South America Biologics Market Size and Forecast, By Disease Category (2024-2032) 9.5.5.2. Rest Of South America Biologics Market Size and Forecast, By Manufacturing (2024-2032) 9.5.5.3. Rest Of South America Biologics Market Size and Forecast, By Product (2024-2032) 9.5.5.4. Rest Of South America Biologics Market Size and Forecast, By Source (2024-2032) 10. Company Profile: Key Players 10.1. AbbVie (USA) 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Recent Developments 10.2. Amgen (USA) 10.3. Biogen (USA) 10.4. Coherus BioSciences (USA) 10.5. Eli Lilly (USA) 10.6. Merck & Co. (USA) 10.7. Pfizer (USA) 10.8. Johnson & Johnson (USA) 10.9. Moderna (USA) 10.10. Bristol-Myers Squibb (USA) 10.11. F. Hoffmann-La Roche (Switzerland) 10.12. Novartis (Switzerland) 10.13. GlaxoSmithKline (UK) 10.14. AstraZeneca (UK) 10.15. Bayer (Germany) 10.16. Boehringer Ingelheim (Germany) 10.17. Fresenius Kabi (Germany) 10.18. Biocon (India) 10.19. Dr. Reddy’s Laboratories (India) 10.20. Intas Pharmaceuticals (India) 10.21. Lupin (India) 10.22. Celltrion (South Korea) 10.23. Samsung Biologics (South Korea) 10.24. LG Chem (South Korea) 10.25. Genor Biopharma (China) 10.26. Julphar (UAE) 10.27. mAbxience (Argentina) 10.28. Eurofarma (Brazil) 10.29. Libbs Farmacêutica (Brazil) 10.30. Blau Farmacêutica (Brazil) 11. Key Findings 12. Industry Recommendations 13. Biologics Market: Research Methodology
